| ASD gene count | Fmr1 | Mecp2 | Mef2a | Mef2d | Nlgn1 | Nlgn3 | Pten | Shank3 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biogroup | Â | Up | Down | Up | Down | Up | Down | Up | down | Up | Down | Up | Down | Up | Down | Up | Down |
TrkA receptor | 8 | Â | 2 | Â | 4 | Â | 2 | Â | 2 | Â | 2 | Â | 3 | 3 | Â | Â | 2 |
Erythropoietin-mediated neuroprotection through NFKB | 7 | 3 | 2 | Â | 3 | Â | 3 | Â | 1 | Â | 2 | Â | 1 | 3 | Â | Â | Â |
PGC1A pathway | 7 | Â | Â | Â | 8 | Â | 5 | Â | 7 | Â | 3 | Â | 4 | Â | 9 | Â | 4 |
Long-term potentiation | 7 | 8 | Â | Â | 18 | Â | 5 | Â | 15 | 3 | Â | Â | Â | Â | 16 | Â | 6 |
Cell adhesion molecules (CAMs) | 7 | Â | Â | 10 | 14 | Â | 8 | Â | 13 | Â | 8 | Â | 11 | 13 | 12 | Â | 10 |
G2 and M phases | 7 | Â | 1 | Â | 1 | Â | 1 | 1 | 1 | Â | 1 | Â | 2 | 3 | Â | Â | Â |
P53 HYPOXIA pathway | 7 | Â | 3 | Â | 3 | Â | 3 | Â | 3 | Â | 2 | Â | 3 | 6 | Â | Â | Â |
Biosynthesis of steroids | 6 | Â | 8 | Â | 5 | Â | Â | Â | 3 | 2 | Â | Â | 5 | Â | 4 | Â | Â |
Arginine and proline metabolism | 6 | Â | 8 | Â | 9 | 1 | Â | Â | 8 | Â | Â | Â | 8 | 5 | Â | Â | Â |
Antigen processing and presentation | 6 | Â | Â | Â | 9 | Â | 3 | Â | 6 | Â | 3 | Â | 10 | Â | Â | Â | 4 |
BAD pathway | 6 | Â | 3 | Â | Â | Â | 3 | Â | 4 | 2 | Â | 2 | Â | Â | Â | Â | 2 |
Neuroregulin receptor degredation protein-1 controls ERBB3 receptor recycling | 6 | Â | Â | 1 | Â | 1 | Â | 1 | Â | 1 | Â | 1 | Â | Â | Â | 1 | Â |
Eicosanoid synthesis | 6 | Â | Â | Â | Â | Â | 1 | Â | 1 | Â | 1 | Â | 1 | 3 | Â | Â | 2 |
Phosphatidylinositol signaling system | 5 | 10 | Â | Â | 17 | Â | Â | Â | Â | Â | 6 | Â | 11 | Â | 10 | Â | Â |
Vitamin B6 metabolism | 5 | 1 | Â | Â | 3 | Â | Â | 1 | 1 | Â | Â | 1 | 2 | Â | 1 | Â | Â |